CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates a specific type of prostate cancer characterized by a deletion in the CHD1 gene. It aims to understand the unique genetic features and treatment responses of these cancers, which may require different therapeutic strategies compared to hormone-driven cancers.
Prostate cancer can be stratified as ETS gene rearranged (ETSR) andnon-rearranged (ETSNR), with the latter comprising a heterogeneousgroup of 50-60% of all cancers.
This project will characterize a subgroupof ETSNR cancers that have a CHD1 deletion (CHD1del).
Recentsequencing studies have elucidated CHD1- cancers as ETSNR, andcommonly PTEN and p53 wildtype and SPOP mutated, comprising up to26% of all prostate cancers (1). ETSR cancers largely have hormonedriven oncogenes that may have prognostic…
INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
